三种氨基水杨酸制剂治疗溃疡性结肠炎的安全性和有效性研究

目的观察美沙拉嗪、奥沙拉嗪和柳氮磺吡啶治疗溃疡性结肠炎的临床疗效和不良反应。方法选择120例轻中度溃疡性结肠炎患者，随机分为美沙拉嗪组（n=40）、奥沙拉嗪组（n=39）和柳氮磺吡啶组（n=41），分别接受上述三种药物治疗。美沙拉嗪组和奥沙拉嗪组患者口服药物剂量均为每次1．0g，每日3次；而柳氮磺吡啶组患者服用剂量为每次1．0g，每日4次。治疗12周后观察治疗疗效和不良反应发生情况。结果美沙拉嗪组、奥沙拉嗪组和柳氮磺吡啶组临床有效率分别为30．0％、28．2％和51．2％，总有效率分别为75．0％、76．9％和92．7％。柳氮磺吡啶组疗效优于美沙拉嗪组、奥沙拉嗪组（P〈0．05）。结论与美沙拉嗪、奥沙拉嗪相比，柳氮磺吡啶治疗溃疡性结肠炎有效性更高，但不良反应发生率稍高。

Study on the safety and efficacy of three amino salicylc acid preparations for treating ulcerative colitis

Objective To evaluate the therapeutic effects of mesalazine, osalazine and sulfasalazine for patientswith ulcerative colitis. Methods 120 patients with ulcerative colitis were randomly divided into mesalazinegroup（n=40）, osalazine group（n=39） and sulfasalazine group（n=41）. The efficacy and adverse events of the three groups were observed after the treatment of 12 weeks. Results The rate of complete remission and overall effective rate of three groupswere30.0%, 28.2% and 51.2%; 75.0%, 76.9% and 92.7%, respectively. And the differences between mesalazine/osalazine and sulfasalazine were statistically significant （P 〈 0.05）. Conclusion Compared with mesalazine and osalazine, sulfasalazine is more effective in treatment of ulcerative colitis, but with a relatively higher incidence of adverse reactions.